investorscraft@gmail.com

Intrinsic value of PetMed Express, Inc. (PETS)

Previous Close$21.35
Intrinsic Value
Upside potential
Previous Close
$21.35

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh10.01 

The original valuation is based on fiscal year data as of 2022-03-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website; telephone contact center; and direct mail/print through brochures and postcards. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2022(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %-11.6NaN
Revenue, $273NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m248NaN
Operating income, $m26NaN
EBITDA, $m28NaN
Interest expense (income), $mNaN
Earnings before tax, $m27NaN
Tax expense, $m6NaN
Net income, $m21NaN

BALANCE SHEET

Cash and short-term investments, $m111NaN
Total assets, $m176NaN
Adjusted assets (=assets-cash), $m65NaN
Average production assets, $m26NaN
Working capital, $m118NaN
Total debt, $m481NaN
Total liabilities, $m34NaN
Total equity, $m142NaN
Debt-to-equity ratio3.380NaN
Adjusted equity ratio0.477NaN

CASH FLOW

Net income, $m21NaN
Depreciation, amort., depletion, $m3NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m18NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-2NaN
Free cash flow, $m20NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m118
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount